1119P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung …
Q Wang, C Ma, T Wang, G Chen, H Wang… - Annals of …, 2022 - annalsofoncology.org
Background Antiangiogenic therapy combined with PD-1/PD-L1 inhibitors has shown
excellent efficacy in advanced NSCLC pts. The ALTER 0303 trial showed that anlotinib …
excellent efficacy in advanced NSCLC pts. The ALTER 0303 trial showed that anlotinib …
300P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung …
XQ Shang, T Wang, G Chen, C Ma, H Wang… - Annals of …, 2022 - annalsofoncology.org
Background Antiangiogenic therapy combined with PD-1/PD-L1 inhibitors has shown
excellent efficacy in advanced NSCLC pts. The ALTER 0303 trial showed that anlotinib …
excellent efficacy in advanced NSCLC pts. The ALTER 0303 trial showed that anlotinib …
1487P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung …
Q Wang, A Xu, C Ma, T Wang, P Liu… - Annals of …, 2023 - annalsofoncology.org
Background Immune checkpoint inhibitors (ICIs) regimens are the cornerstone of first-line
treatment of advanced non-small cell lung cancer (NSCLC). Anlotinib is a multi-targeted …
treatment of advanced non-small cell lung cancer (NSCLC). Anlotinib is a multi-targeted …
[HTML][HTML] Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study
X Ye, A Huang, Y Zhou, Y Kuang, W Wang… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Background Programmed cell death 1 (PD-1) inhibitors are beneficial for patients with
advanced lung cancer. However, the population who will benefit from PD-1 inhibitors is …
advanced lung cancer. However, the population who will benefit from PD-1 inhibitors is …
Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer
H Cao, K Liang, P Liu, J Wang, Y Ji, L Xu… - Oncology and …, 2020 - journals.lww.com
Objective Anlotinib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor,
has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays, and has …
has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays, and has …
166P First-line anlotinib-based combination treatment for patients with advanced non-small cell lung cancer: A threearm, prospective study
B Han, T Chu, W Zhang, X Zhang, C Shi, R Zhong… - Journal of Thoracic …, 2021 - jto.org
Background: Anlotinib, an oral multi-target TKI antiangiogenic Inhibitor, has been
recommended by guidelines for the 3rd line or more treatment of NSCLC in China, but its …
recommended by guidelines for the 3rd line or more treatment of NSCLC in China, but its …
Efficacy and safety of Anlotinib plus PD-1 blockade for the treatment of advanced non-small cell lung cancer: A Retrospective study
X Pan, A Dai - 2022 - researchsquare.com
Purpose: Both anlotinib and programmed cell death protein 1 (PD-1) have been
demonstrated anti-tumor efficacy in non-small cell lung cancer (NSCLC) in clinical …
demonstrated anti-tumor efficacy in non-small cell lung cancer (NSCLC) in clinical …
P40. 06 A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer
J Wang, T Yi, Y Dong, R Ran, F Cao, Y Li, Z Luo… - Journal of Thoracic …, 2021 - jto.org
Methods This study is a non-interventional, prospective, multi-center observational study of
real world cases and all registered data are collected from real clinical practice cases. Adult …
real world cases and all registered data are collected from real clinical practice cases. Adult …
[PDF][PDF] E cacy and safety of Anlotinib plus PD-1 blockade for the treatment of advanced non-small cell lung cancer: A Retrospective study
X Pan, A Dai - scholar.archive.org
Purpose: Both anlotinib and programmed cell death protein 1 (PD-1) have been
demonstrated anti-tumor efficacy in non-small cell lung cancer (NSCLC) in clinical …
demonstrated anti-tumor efficacy in non-small cell lung cancer (NSCLC) in clinical …
[HTML][HTML] The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer
C Zhai, X Zhang, L Ren, L You, Q Pan, H Pan… - Frontiers in …, 2021 - frontiersin.org
Background Both anlotinib and programmed death 1 (PD-1) monoclonal antibody (mAb)
have been approved for the third line treatment of metastatic non-small cell lung cancer …
have been approved for the third line treatment of metastatic non-small cell lung cancer …